CA2298681A1 - Methods and compositions for overcoming resistance to biologic and chemotherapy - Google Patents
Methods and compositions for overcoming resistance to biologic and chemotherapy Download PDFInfo
- Publication number
- CA2298681A1 CA2298681A1 CA002298681A CA2298681A CA2298681A1 CA 2298681 A1 CA2298681 A1 CA 2298681A1 CA 002298681 A CA002298681 A CA 002298681A CA 2298681 A CA2298681 A CA 2298681A CA 2298681 A1 CA2298681 A1 CA 2298681A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- prodrug
- endogenous
- biologic
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
- G01N2333/91011—Methyltransferases (general) (2.1.1.)
Abstract
This invention provides a method for identifying potential therapeutic agents by contacting a target cell with a candidate therapeutic agent which is a selective substrate for an endogenous, intracellular enzyme in the cell which is enhanced in its expression as a result of selection by biologic or chemotherapy. This invention also provides methods and examples of molecules for selectively killing a pathological cell by contacting the cell with a prodrug that is a selective substrate for an endogenous, intracellular enzyme. The prodrug is subsequently converted to a cellular toxin. Futher provided by this invention is a method for treating a pathology characterized by pathological, hyperproliferative cells in a subject by administering to the subject a prodrug that is a selective substrate for an endogenous, overexpressed, intracellular enzyme, and converted by the enzyme to a cellular toxin in the hyperproliferative cell.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5552597P | 1997-08-08 | 1997-08-08 | |
US60/055,525 | 1997-08-08 | ||
PCT/US1998/016607 WO1999008110A1 (en) | 1997-08-08 | 1998-08-07 | Methods and compositions for overcoming resistance to biologic and chemotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2298681A1 true CA2298681A1 (en) | 1999-02-18 |
CA2298681C CA2298681C (en) | 2008-07-08 |
Family
ID=21998430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002298681A Expired - Fee Related CA2298681C (en) | 1997-08-08 | 1998-08-07 | Methods and compositions for overcoming resistance to biologic and chemotherapy |
Country Status (9)
Country | Link |
---|---|
US (3) | US6495553B1 (en) |
EP (1) | EP1004022A4 (en) |
JP (3) | JP2001512830A (en) |
CN (1) | CN1307421C (en) |
AT (1) | ATE413881T1 (en) |
AU (1) | AU9016998A (en) |
CA (1) | CA2298681C (en) |
DE (1) | DE69840216D1 (en) |
WO (1) | WO1999008110A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999008110A1 (en) * | 1997-08-08 | 1999-02-18 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
EP1045897B1 (en) * | 1998-01-23 | 2002-01-30 | Newbiotics Inc. | Enzyme catalyzed therapeutic agents |
WO2001007088A2 (en) * | 1999-07-22 | 2001-02-01 | Newbiotics, Inc. | Methods for treating therapy-resistant tumors |
EP1200455B1 (en) * | 1999-07-22 | 2009-04-22 | Celmed Oncology (USA), Inc. | Enzyme catalyzed therapeutic activation |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
US20030212037A1 (en) * | 2000-12-21 | 2003-11-13 | Christopher Boyer | Use of bvdu for inhibiting the growth of hyperproliferative cells |
US7514067B2 (en) * | 2000-04-25 | 2009-04-07 | President And Fellows Of Harvard College | Methods for tumor diagnosis and therapy |
WO2002007780A2 (en) * | 2000-07-20 | 2002-01-31 | Newbiotics, Inc. | Methods for identifying therapeutic targets |
EP1683874A3 (en) * | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
AU2002241911B9 (en) | 2001-01-19 | 2007-01-25 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
EP1399467A4 (en) | 2001-05-09 | 2004-09-15 | Newbiotics Inc | Peptide deformylase activated prodrugs |
US20040235761A1 (en) * | 2001-08-14 | 2004-11-25 | Yousuke Furuta | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue |
JP2005514359A (en) * | 2001-11-23 | 2005-05-19 | 中外製薬株式会社 | Identification of tumor-targeting enzymes |
US20030152747A1 (en) * | 2002-01-11 | 2003-08-14 | The Garland Company, Inc., An Ohio Corporation | Roofing materials |
JP4502641B2 (en) * | 2002-01-24 | 2010-07-14 | ティルタン ファーマ リミテッド | Anti-cancer combinations and methods of use |
US6987180B2 (en) | 2002-02-07 | 2006-01-17 | President And Fellows Of Harvard College | Uridine analogs and techniques for making and using |
US20040101915A1 (en) * | 2002-06-18 | 2004-05-27 | Irm Llc, A Delaware Limited Liability Company | Diagnosis and treatment of chemoresistant tumors |
US7001922B2 (en) | 2002-11-14 | 2006-02-21 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
US7595400B2 (en) * | 2003-02-21 | 2009-09-29 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic compounds |
MXPA06011679A (en) * | 2004-04-09 | 2007-01-23 | Chugai Pharmaceutical Co Ltd | Novel water-soluble prodrug. |
KR101347830B1 (en) | 2004-05-23 | 2014-01-07 | 에이치엠아이, 인코포레이티드 | Theramutein modulators |
TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
KR20080066039A (en) * | 2005-10-19 | 2008-07-15 | 추가이 세이야쿠 가부시키가이샤 | Agent for preventing or treating pancreas cancer, ovary cancer or liver cancer containing novel water-soluble prodrug |
US8877785B2 (en) | 2009-09-04 | 2014-11-04 | Tactical Therapeutics Inc | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate |
CN113917023B (en) * | 2021-10-08 | 2024-03-19 | 湖南慧泽生物医药科技有限公司 | Method for determining the concentration of brivudine in human plasma |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US165199A (en) * | 1875-07-06 | Improvement in eyeglasses | ||
US119094A (en) * | 1871-09-19 | Improvement in bungs and bung-inserters | ||
US22001A (en) * | 1858-11-02 | Billiard-table | ||
US34473A (en) * | 1862-02-25 | Improved digging-machine | ||
US668A (en) * | 1838-04-02 | Improvement in wardrobe-bedsteads | ||
US95921A (en) * | 1869-10-19 | Horace a | ||
US49201A (en) * | 1865-08-01 | Improved composition for paint | ||
GB982776A (en) | 1962-01-24 | 1965-02-10 | Wellcome Found | 2-deoxyuridines and their use in pharmaceutical compositions having anti-immune activity |
JPS5017989B1 (en) | 1970-12-24 | 1975-06-25 | ||
US4267171A (en) | 1979-07-02 | 1981-05-12 | The Regents Of The University Of California | C-5 Substituted cytosine nucleosides |
US4247544A (en) | 1979-07-02 | 1981-01-27 | The Regents Of The University Of California | C-5 Substituted uracil nucleosides |
JPS5843993A (en) | 1981-09-09 | 1983-03-14 | Yamasa Shoyu Co Ltd | 1-beta-d-arabinofuranosyl-(e)-5-(2-halogenovinyl)uracil-5'- phosphoric acid and its preparation |
EP0095294A1 (en) | 1982-05-22 | 1983-11-30 | Beecham Group Plc | Deoxyuridine compounds, methods for preparing them and their use in medicine |
DE3229169A1 (en) | 1982-08-05 | 1984-02-09 | Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen | Use of 5-alkylpyrimidine nucleosides and their derivatives as cytostatics |
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US5077283A (en) | 1986-10-23 | 1991-12-31 | American Cyanamid Company | Solubilized imidazole pro-drugs |
US5212291A (en) | 1986-10-23 | 1993-05-18 | American Cyanamid Company | Anthracycline derivatives as solubilized pro-drugs |
US5077282A (en) | 1986-10-23 | 1991-12-31 | American Cyanamid Company | Solubilized pro-drugs |
US5116827A (en) | 1986-10-23 | 1992-05-26 | American Cyanamid Company | Quinolinecarboxylic acid derivatives as solubilized pro-drugs |
US5070082A (en) | 1986-10-23 | 1991-12-03 | American Cyanamid Company | Solubilized pro-drugs |
US4963533A (en) * | 1986-10-24 | 1990-10-16 | Stichting Rega Vzw (Rega) | Therapeutic application of dideoxycytidinene |
US5116822A (en) * | 1986-10-24 | 1992-05-26 | Stichting Rega Vzw | Therapeutic application of dideoxycytidinene |
NL8700366A (en) | 1987-02-13 | 1988-09-01 | Stichting Rega V Z W | COMBINATION OF FU WITH BVDU AS AN AGENT AGAINST ADENOCARCINOMA. |
US5085983A (en) | 1988-08-19 | 1992-02-04 | City Of Hope | Detection of human tumor progression and drug resistance |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
CA1317291C (en) | 1987-12-14 | 1993-05-04 | Naeem Botros Hanna | Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds |
DE68917479D1 (en) | 1988-02-24 | 1994-09-15 | Inst Rech Chim Biolog | DERIVATIVES OF DEOXY-2'-URIDINE SUBSTITUTED IN THE 5, 3 'OR 5' POSITION BY ACYLATED ALPHA-AMINO GROUPS, METHOD FOR THE PRODUCTION AND MEDICINAL PRODUCTS THEREOF. |
WO1990003978A1 (en) | 1988-10-03 | 1990-04-19 | Stichting Rega Vzw | 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application |
HU215909B (en) * | 1989-12-20 | 1999-03-29 | Schering Corp. | Process for producing bcrf1 proteins as inhibitors of gamma-interferon and pharmaceutical preparations containing them |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9010242D0 (en) | 1990-05-08 | 1990-06-27 | British Telecomm | Optical signal regenerator and optical communications system incorporating same |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5556942A (en) * | 1991-04-29 | 1996-09-17 | Terrapin Technologies, Inc. | Glutathione S-transferase-activated compounds |
US5645988A (en) | 1991-05-08 | 1997-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of identifying drugs with selective effects against cancer cells |
DE19875016I2 (en) | 1991-05-16 | 2004-07-01 | Glaxo Group Ltd | Antivirus preparations containing nucleoside analogs. |
US5233031A (en) | 1991-09-23 | 1993-08-03 | University Of Rochester | Phosphoramidate analogs of 2'-deoxyuridine |
US5274162A (en) * | 1991-12-13 | 1993-12-28 | Arnold Glazier | Antineoplastic drugs with bipolar toxification/detoxification functionalities |
WO1993013740A2 (en) | 1991-12-31 | 1993-07-22 | Worcester Foundation For Experimental Biology | Antiparasitic oligonucleotides active against drug resistant malaria |
US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
US5409632A (en) * | 1992-11-16 | 1995-04-25 | The Procter & Gamble Company | Cleaning and bleaching composition with amidoperoxyacid |
IL105244A (en) | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
US5502037A (en) | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
DE69425379T2 (en) | 1993-09-21 | 2000-11-30 | Amersham Pharm Biotech Uk Ltd | ELONGATION, AMPLIFICATION AND SEQUENCING USING A CHIMERIC OLIGONUCLEOTID |
US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5521161A (en) | 1993-12-20 | 1996-05-28 | Compagnie De Developpment Aguettant S.A. | Method of treating HIV in humans by administration of ddI and hydroxycarbamide |
JPH07264309A (en) * | 1994-03-18 | 1995-10-13 | Fujitsu Ltd | Incoming call controller |
GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
US5968910A (en) * | 1994-11-30 | 1999-10-19 | Jan M. R. Balzarini | Compositions containing two or three inhibitors of different HIV reverse transcriptases |
DK0806956T3 (en) | 1995-02-01 | 2003-01-06 | Resprotect Gmbh | Use of 5-substituted nucleosides to inhibit resistance formation by cytostatic therapy |
US5705336A (en) * | 1995-03-07 | 1998-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Assay for sensitivity of tumors to DNA-platinating chemotherapy |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
IL117940A (en) | 1995-04-19 | 2003-06-24 | Kumiai Chemical Industry Co | Benzylsulfide derivatives, process for their production and insecticide compositions containing them |
US5856464A (en) | 1995-06-07 | 1999-01-05 | Lajolla Pharmaceutical Company | Selective capping solution phase oligonucleotide synthesis |
US5998151A (en) * | 1995-12-01 | 1999-12-07 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase |
WO1997021452A2 (en) | 1995-12-14 | 1997-06-19 | Advanced Magnetics, Inc. | Macromolecular prodrugs of nucleotide analogs |
US6149904A (en) * | 1996-01-31 | 2000-11-21 | The Regents Of The University Of California | Method for inhibiting tumor cell growth by administering to tumor cells expressing a nucleic acid encoding a connexin and a pro-drug |
GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
WO1999006072A1 (en) | 1997-07-30 | 1999-02-11 | Boehringer Mannheim Corporation | Cyclized prodrugs |
WO1999008110A1 (en) * | 1997-08-08 | 1999-02-18 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
AU1197699A (en) | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
ATE287414T1 (en) | 1997-10-30 | 2005-02-15 | Us Gov Health & Human Serv | ANTITUMORAL URIDINE DERIVATIVES |
EP1045897B1 (en) * | 1998-01-23 | 2002-01-30 | Newbiotics Inc. | Enzyme catalyzed therapeutic agents |
US6683061B1 (en) * | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
AU2002236455A1 (en) * | 2000-11-16 | 2002-05-27 | Newbiotics, Inc. | Synergistic ecta compositions |
AU2002241911B9 (en) * | 2001-01-19 | 2007-01-25 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
JP3813490B2 (en) | 2001-10-30 | 2006-08-23 | 富士通株式会社 | Spread spectrum rake receiver |
-
1998
- 1998-08-07 WO PCT/US1998/016607 patent/WO1999008110A1/en not_active Application Discontinuation
- 1998-08-07 EP EP98942031A patent/EP1004022A4/en not_active Withdrawn
- 1998-08-07 AT AT02012895T patent/ATE413881T1/en not_active IP Right Cessation
- 1998-08-07 CN CNB988079682A patent/CN1307421C/en not_active Expired - Fee Related
- 1998-08-07 AU AU90169/98A patent/AU9016998A/en not_active Abandoned
- 1998-08-07 US US09/130,839 patent/US6495553B1/en not_active Expired - Lifetime
- 1998-08-07 CA CA002298681A patent/CA2298681C/en not_active Expired - Fee Related
- 1998-08-07 JP JP2000506527A patent/JP2001512830A/en active Pending
- 1998-08-07 DE DE69840216T patent/DE69840216D1/en not_active Expired - Lifetime
-
2001
- 2001-02-20 US US09/789,226 patent/US7465734B2/en not_active Expired - Fee Related
- 2001-11-12 JP JP2001345616A patent/JP2002223790A/en active Pending
- 2001-11-12 JP JP2001346379A patent/JP2002167337A/en active Pending
-
2005
- 2005-01-12 US US11/034,036 patent/US20050123983A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69840216D1 (en) | 2008-12-24 |
US7465734B2 (en) | 2008-12-16 |
US6495553B1 (en) | 2002-12-17 |
WO1999008110A1 (en) | 1999-02-18 |
AU9016998A (en) | 1999-03-01 |
EP1004022A4 (en) | 2000-10-25 |
JP2002167337A (en) | 2002-06-11 |
EP1004022A1 (en) | 2000-05-31 |
CA2298681C (en) | 2008-07-08 |
JP2001512830A (en) | 2001-08-28 |
CN1307421C (en) | 2007-03-28 |
US20050123983A1 (en) | 2005-06-09 |
JP2002223790A (en) | 2002-08-13 |
ATE413881T1 (en) | 2008-11-15 |
US20010016329A1 (en) | 2001-08-23 |
CN1265741A (en) | 2000-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2298681A1 (en) | Methods and compositions for overcoming resistance to biologic and chemotherapy | |
EP1167972A3 (en) | Enzyme catalyzed therapeutic agents | |
ES2159318T3 (en) | INHIBITORS OF PROTEIN QUINASA C. | |
WO2001072962A3 (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
WO2003097803A3 (en) | Cancer-linked gene as target for chemotherapy | |
WO2003101400A3 (en) | Cancer-linked gene as target for chemotherapy | |
EP1436316A4 (en) | Subcellular targeting of therapeutic proteins | |
NO993943D0 (en) | Combined tumor suppressor therapy and chemotherapy in the treatment of neoplasms | |
DE69824597D1 (en) | IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHOD | |
WO2002068680A3 (en) | Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes | |
NZ334518A (en) | Homocysteine desulphurase from the protozoan trichomonas vaginalis | |
WO2001016334A3 (en) | Human hydrolytic enzymes | |
WO2000050565A3 (en) | Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene | |
WO2005019475A3 (en) | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) | |
EP1019092A4 (en) | Therapeutic and diagnostic tools for impaired glucose tolerance conditions | |
EP1240922A3 (en) | Methods and compositions for overcoming resistance to biologic and chemotherapy | |
WO2003077875A3 (en) | Proteins associated with growth, differentiation, and death | |
WO2000018907A3 (en) | Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1 | |
WO2002074921A3 (en) | Methods for isolating proteins expressed by dendritic cells | |
WO1999065450A3 (en) | Immunosuppressive agents that inhibit calcineurin function and uses thereof | |
WO2001083524A3 (en) | Rna metabolism proteins | |
WO2003076579A3 (en) | Cancer-linked gene as target for chemotherapy | |
WO2003097802A3 (en) | Cancer-linked gene as target for chemotherapy | |
WO2004017909A3 (en) | Methods of reducing ischemic injury | |
WO2003095622A3 (en) | Proteins associated with cell growth, differentiation, and death |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160808 |